ANDA 214202, held by Teva Pharmaceuticals USA. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 214202 (Methylphenidate Hydrochloride), held by Teva Pharmaceuticals USA, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 7, 2023 | Original application | Tentative approval | None posted |
| Methylphenidate Hydrochloride20MG · tablet, extended release, chewable;oral | Methylphenidate Hydrochloride | None (tentative approval) |
| Methylphenidate Hydrochloride30MG · tablet, extended release, chewable;oral | Methylphenidate Hydrochloride | None (tentative approval) |
| Methylphenidate Hydrochloride40MG · tablet, extended release, chewable;oral | Methylphenidate Hydrochloride | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters